An Investigator Initiated Trial to Evaluate the Safety and Feasibility of the DyNETIC-35 Stent for Iliac Lesions Via a Trans-radial Approach

Last updated: January 25, 2023
Sponsor: Klinikum Arnsberg
Overall Status: Active - Recruiting

Phase

N/A

Condition

Claudication

Vascular Diseases

Peripheral Arterial Occlusive Disease

Treatment

N/A

Clinical Study ID

NCT05372952
ASL202201
  • Ages > 18
  • All Genders

Study Summary

This feasibility study with a 30 day follow up period will assess the safety and feasibility of the Dynetic-35 stent for the treatment of peripheral iliac artery lesions via a trans-radial approach.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subject is ≥ 18 years
  2. Subject is capable (no legally authorized representative allowed) to provide writteninformed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site prior to any study related procedure
  3. Subject has provided written informed consent before any study specific test orprocedure and is willing to comply with all protocol and follow-up requirements
  4. Subjects have a target lesion(s) with ≥ 70% stenosis (visual estimate) located in theiliac arteries
  5. Target lesion is a de novo, restenotic or occluded lesion
  6. Reference lumen (vessel) diameter between 5mm and 10 mm
  7. The target lesion can be successfully crossed with a guide wire
  8. Patient is eligible for transradial access
  9. Subject has symptomatic iliac artery disease defined as Rutherford category 2 orhigher

Exclusion

Exclusion Criteria:

  1. Subject is pregnant and/or breastfeeding or planning to become pregnant during thecourse of the study.
  2. Subject is with a current medical condition with a life expectancy of less than oneyear.
  3. Pre-existing target iliac artery aneurysm or perforation or dissection
  4. Any medical condition that in the opinion of the investigator poses an unacceptablerisk for implant of a stent according to the study indications like, sensitivity tometal ions, intolerance to contrast or antiplatelet, anticoagulant or thrombolyticmedications required per the protocol
  5. Abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion requiringtreatment
  6. The subject is currently participating in an investigational drug, biologic, oranother device study and has not reached their primary endpoint yet
  7. Subjects with small diameter upper extremity arteries that posed a contraindication tothe use of 6F sheath
  8. Severe stenosis or calcification of upper extremity arteries
  9. Patient height precluding transradial access with a 170 cm long catheter shaft
  10. Patient with a history of aortic arch atheroembolism
  11. Infrainguinal outflow lesions that need to be treated during the same index procedure
  12. Patients with negative bilateral Allen or barbeau tests (Note: vascular access shouldbe done via the left hand where possible)
  13. Subject has IFU listed contraindication(s)
  14. Subject has in-stent restenosis

Study Design

Total Participants: 25
Study Start date:
July 25, 2022
Estimated Completion Date:
August 31, 2023

Connect with a study center

  • Vascular center of Klinikum Hochsauerland GmbH

    Arnsberg, 59759
    Germany

    Site Not Available

  • Oberlausitz Kliniken

    Bautzen, 02625
    Germany

    Active - Recruiting

  • Bonifatius Klinikum Lingen

    Lingen, 49808
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.